1
|
In situ forming phase-inversion implants for sustained ocular delivery of triamcinolone acetonide. Drug Deliv Transl Res 2019; 9:534-542. [PMID: 29484530 DOI: 10.1007/s13346-018-0491-y] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
The objectives of this study were to develop biodegradable poly-lactic-co-glycolic acid (PLGA) based injectable phase inversion in situ forming system for sustained delivery of triamcinolone acetonide (TA) and to conduct physicochemical characterisation including in vitro drug release of the prepared formulations. TA (at 0.5%, 1% and 2.5% w/w loading) was dissolved in N-methyl-2-pyrrolidone (NMP) solvent and then incorporated 30% w/w PLGA (50/50 and 75/25) polymer to prepare homogenous injectable solution. The formulations were evaluated for rheological behaviour using rheometer, syringeability by texture analyser, water uptake and rate of implant formation by optical coherence tomography (OCT) microscope. Phase inversion in situ forming formulations were injected into PBS pH 7.3 to form an implant and release samples were collected and analysed for drug content using a HPLC method. All formulations exhibited good syringeability and rheological properties (viscosity: 0.19-3.06 Pa.s) by showing shear thinning behaviour which enable them to remain as free-flowing solution for ease administration. The results from OCT microscope demonstrated that thickness of the implants were increased with the increase in time and the rate of implant formation indicated the fast phase inversion. The drug release from implants was sustained over a period of 42 days. The research findings demonstrated that PLGA/NMP-based phase inversion in situ forming implants can improve compliance in patient's suffering from ocular diseases by sustaining the drug release for a prolonged period of time and thereby reducing the frequency of ocular injections.
Collapse
|
2
|
Carrera I, Cacabelos R. Current Drugs and Potential Future Neuroprotective Compounds for Parkinson's Disease. Curr Neuropharmacol 2019; 17:295-306. [PMID: 30479218 PMCID: PMC6425078 DOI: 10.2174/1570159x17666181127125704] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Revised: 10/29/2018] [Accepted: 11/22/2018] [Indexed: 12/21/2022] Open
Abstract
The research progress of understanding the etiology and pathogenesis of Parkinson's disease (PD) has yet lead to the development of some clinical approaches intended to treat cognitive and behavioral symptoms, such as memory and perception disorders. Despite the major advances in different genetic causes and risk factors for PD, which share common pathways to cell dysfunction and death, there is not yet a complete model of PD that can be used to accurately predict the effect of drugs on disease progression. Clinical trials are also important to test any novel neuro-protective agent, and recently there have been great advances in the use of anti-inflammatory drugs and plant flavonoid antioxidants to protect against specific neuronal degeneration and its interference with lipid and cholesterol metabolism. The increasing knowledge of the molecular events underlying the degenerative process of PD has stimulated research to identify natural compounds capable of halting or slowing the progress of neural deterioration. Polyphenols and flavonoids, which play a neuroprotective role in a wide array of in vitro and in vivo models of neurological disorders, emerged from among the multi-target bio-agents found mainly in plants and microorganisms. This review presents a detailed overview of the multimodal activities of neuroprotective bio-agents tested so far, emphasizing their neurorescue/neuroregenerative activity. The brain-penetrating property of bioagents may make these compounds an important class of natural drugs for the treatment of neurodegenerative diseases. Although there are numerous studies demonstrating beneficial effects in the laboratory by identifying critical molecular targets, the clinical efficacy of these neuroprotective treatments remains to be proven accurately.
Collapse
Affiliation(s)
- Iván Carrera
- Address correspondence to this author at the Department of Health Biotechnology, EuroEspes Biomedical Research Center, 15165 Bergondo, Corunna, Spain; Tel: +34 981780505; E-mail:
| | | |
Collapse
|
3
|
In situ formation of injectable chitosan-gelatin hydrogels through double crosslinking for sustained intraocular drug delivery. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2018; 88:1-12. [DOI: 10.1016/j.msec.2018.02.022] [Citation(s) in RCA: 82] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Revised: 10/30/2017] [Accepted: 02/22/2018] [Indexed: 01/10/2023]
|
4
|
Li TP, Wong WP, Chen LC, Su CY, Chen LG, Liu DZ, Ho HO, Sheu MT. Physical and Pharmacokinetic Characterizations of trans-Resveratrol (t-Rev) Encapsulated with Self-Assembling Lecithin-based Mixed Polymeric Micelles (saLMPMs). Sci Rep 2017; 7:10674. [PMID: 28878397 PMCID: PMC5587738 DOI: 10.1038/s41598-017-11320-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2017] [Accepted: 08/22/2017] [Indexed: 12/18/2022] Open
Abstract
This study involved physical and pharmacokinetic characterizations of trans-resveratrol (t-Rev)-loaded saLMPMs which attempted to improve t-Rev’s pharmacokinetic profiles and bioavailability resolving hurdles limiting its potential health benefits. The optimal formulation consisted of t-Rev, lecithin, and Pluronic® P123 at 5:2:20 (t-Rev-loaded PP123 saLMPMs) provided mean particle size <200 nm, encapsulation efficiency >90%, and drug loading >15%. Compared to t-Rev solubilized with HP-β-CD, t-Rev-loaded PP123 saLMPMs enhanced t-Rev’s stability in PBS at RT, 4 °C, and 37 °C and in FBS at 37 °C, and retarded the in vitro release. Intravenous administration of t-Rev-loaded PP123 saLMPMs was able to enhance 40% absolute bioavailability and a greater portion of t-Rev was found to preferably distribute into peripheral compartment potentially establishing a therapeutic level at the targeted site. With oral administration, t-Rev-loaded LMPMs increases 2.17-fold absolute bioavailability and furnished a 3-h period of time in which the plasma concentration maintained above the desirable concentration for chemoprevention and accomplished a higher value of the dose-normalized area under the curve for potentially establishing an effective level at the target site. Therefore, intravenous and oral pharmacokinetic characteristics of t-Rev encapsulated with PP123 saLMPMs indicate that t-Rev can be translated into a clinically useful therapeutic agent.
Collapse
Affiliation(s)
- Tzu-Pin Li
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan, ROC
| | - Wan-Ping Wong
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan, ROC
| | - Ling-Chun Chen
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan, ROC.,Department of Biotechnology and Pharmaceutical Technology, Yuanpei University of Medical Technology, Hsinchu, Taiwan, ROC
| | - Chia-Yu Su
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan, ROC
| | - Lih-Geeng Chen
- Department of Microbiology, Immunology, and Biopharmaceutics, National Chiayi University, Chiayi, Taiwan, ROC
| | - Der-Zen Liu
- Graduate Institute of Biomedical Materials and Engineering, Taipei Medical University, Taipei, Taiwan, ROC
| | - Hsiu-O Ho
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan, ROC.
| | - Ming-Thau Sheu
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan, ROC. .,Clinical Research Center and Traditional Herbal Medicine Research Center, Taipei Medical University Hospital, Taipei, Taiwan, ROC.
| |
Collapse
|
5
|
Shang H, Chen X, Liu Y, Yu L, Li J, Ding J. Cucurbit[7]-assisted sustained release of human calcitonin from thermosensitive block copolymer hydrogel. Int J Pharm 2017; 527:52-60. [DOI: 10.1016/j.ijpharm.2017.05.006] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2017] [Revised: 04/18/2017] [Accepted: 05/03/2017] [Indexed: 11/28/2022]
|
6
|
Liang R, Luo Z, Pu G, Wu W, Shi S, Yu J, Zhang Z, Chen H, Li X. Self-assembled peptide-based supramolecular hydrogel for ophthalmic drug delivery. RSC Adv 2016. [DOI: 10.1039/c6ra11691d] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Conventional ophthalmic formulations such as eye drops normally suffer from limited therapeutic efficacy with a requirement for frequent instillation.
Collapse
Affiliation(s)
- Renlong Liang
- Institute of Biomedical Engineering
- School of Ophthalmology & Optometry and Eye Hospital
- Wenzhou Medical University
- Wenzhou 325027
- P. R. China
| | - Zichao Luo
- Institute of Biomaterials and Engineering
- Wenzhou Medical University
- Wenzhou 325035
- P. R. China
- Wenzhou Institute of Biomaterials and Engineering
| | - Guojuan Pu
- Institute of Biomaterials and Engineering
- Wenzhou Medical University
- Wenzhou 325035
- P. R. China
- Wenzhou Institute of Biomaterials and Engineering
| | - Wei Wu
- Institute of Biomedical Engineering
- School of Ophthalmology & Optometry and Eye Hospital
- Wenzhou Medical University
- Wenzhou 325027
- P. R. China
| | - Shuai Shi
- Institute of Biomedical Engineering
- School of Ophthalmology & Optometry and Eye Hospital
- Wenzhou Medical University
- Wenzhou 325027
- P. R. China
| | - Jing Yu
- Institute of Biomaterials and Engineering
- Wenzhou Medical University
- Wenzhou 325035
- P. R. China
- Wenzhou Institute of Biomaterials and Engineering
| | - Zhaoliang Zhang
- Institute of Biomedical Engineering
- School of Ophthalmology & Optometry and Eye Hospital
- Wenzhou Medical University
- Wenzhou 325027
- P. R. China
| | - Hao Chen
- Institute of Biomedical Engineering
- School of Ophthalmology & Optometry and Eye Hospital
- Wenzhou Medical University
- Wenzhou 325027
- P. R. China
| | - Xingyi Li
- Institute of Biomedical Engineering
- School of Ophthalmology & Optometry and Eye Hospital
- Wenzhou Medical University
- Wenzhou 325027
- P. R. China
| |
Collapse
|
8
|
Reimondez-Troitiño S, Csaba N, Alonso MJ, de la Fuente M. Nanotherapies for the treatment of ocular diseases. Eur J Pharm Biopharm 2015; 95:279-93. [PMID: 25725262 DOI: 10.1016/j.ejpb.2015.02.019] [Citation(s) in RCA: 115] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Revised: 02/09/2015] [Accepted: 02/16/2015] [Indexed: 10/23/2022]
Abstract
The topical route is the most frequent and preferred way to deliver drugs to the eye. Unfortunately, the very low ocular drug bioavailability (less than 5%) associated with this modality of administration, makes the efficient treatment of several ocular diseases a significant challenge. In the last decades, it has been shown that specific nanocarriers can interact with the ocular mucosa, thereby increasing the retention time of the associated drug onto the eye, as well as its permeability across the corneal and conjunctival epithelium. In this review, we comparatively analyze the mechanism of action and specific potential of the most studied nano-drug delivery carriers. In addition, we present the success achieved until now using a number of nanotherapies for the treatment of the most prevalent ocular pathologies, such as infections, inflammation, dry eye, glaucoma, and retinopathies.
Collapse
Affiliation(s)
- S Reimondez-Troitiño
- Nano-oncologicals Lab, Translational Medical Oncology Group, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital of Santiago de Compostela (CHUS), Santiago de Compostela, Spain; Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Health Research Institute of Santiago de Compostela (IDIS), Dept. of Pharmacy and Pharmaceutical Technology, School of Pharmacy, Univ. of Santiago de Compostela, Santiago de Compostela, Spain
| | - N Csaba
- Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Health Research Institute of Santiago de Compostela (IDIS), Dept. of Pharmacy and Pharmaceutical Technology, School of Pharmacy, Univ. of Santiago de Compostela, Santiago de Compostela, Spain
| | - M J Alonso
- Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Health Research Institute of Santiago de Compostela (IDIS), Dept. of Pharmacy and Pharmaceutical Technology, School of Pharmacy, Univ. of Santiago de Compostela, Santiago de Compostela, Spain
| | - M de la Fuente
- Nano-oncologicals Lab, Translational Medical Oncology Group, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital of Santiago de Compostela (CHUS), Santiago de Compostela, Spain.
| |
Collapse
|